Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.
Identifieur interne : 001737 ( Main/Corpus ); précédent : 001736; suivant : 001738Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.
Auteurs : Emily LittlejohnSource :
- Cleveland Clinic journal of medicine [ 1939-2869 ] ; 2020.
Abstract
Hydroxychloroquine (HCQ) is in short supply as a result of the coronavirus disease 2019 (COVID-19) pandemic, presenting a challenge to rheumatologists to ensure their patients with systemic lupus erythematosus (SLE) continue to take this essential drug. HCQ is the only SLE treatment shown to increase survival and any change in the HCQ regimen is potentially dangerous. Changes in the HCQ regimen should be made jointly with the patient after a discussion of the available evidence and expert opinion and the patient's preferences. Providers need to make thoughtful, informed decisions in this time of medication shortage.
DOI: 10.3949/ccjm.87a.ccc023
PubMed: 32393597
Links to Exploration step
pubmed:32393597Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.</title><author><name sortKey="Littlejohn, Emily" sort="Littlejohn, Emily" uniqKey="Littlejohn E" first="Emily" last="Littlejohn">Emily Littlejohn</name><affiliation><nlm:affiliation>Department of Rheumatologic and Immunologic Disease, Cleveland Clinic.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32393597</idno><idno type="pmid">32393597</idno><idno type="doi">10.3949/ccjm.87a.ccc023</idno><idno type="wicri:Area/Main/Corpus">001737</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001737</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.</title><author><name sortKey="Littlejohn, Emily" sort="Littlejohn, Emily" uniqKey="Littlejohn E" first="Emily" last="Littlejohn">Emily Littlejohn</name><affiliation><nlm:affiliation>Department of Rheumatologic and Immunologic Disease, Cleveland Clinic.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Cleveland Clinic journal of medicine</title><idno type="eISSN">1939-2869</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hydroxychloroquine (HCQ) is in short supply as a result of the coronavirus disease 2019 (COVID-19) pandemic, presenting a challenge to rheumatologists to ensure their patients with systemic lupus erythematosus (SLE) continue to take this essential drug. HCQ is the only SLE treatment shown to increase survival and any change in the HCQ regimen is potentially dangerous. Changes in the HCQ regimen should be made jointly with the patient after a discussion of the available evidence and expert opinion and the patient's preferences. Providers need to make thoughtful, informed decisions in this time of medication shortage.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32393597</PMID><DateRevised><Year>2020</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1939-2869</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>Cleveland Clinic journal of medicine</Title><ISOAbbreviation>Cleve Clin J Med</ISOAbbreviation></Journal><ArticleTitle>Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ccc023</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3949/ccjm.87a.ccc023</ELocationID><Abstract><AbstractText>Hydroxychloroquine (HCQ) is in short supply as a result of the coronavirus disease 2019 (COVID-19) pandemic, presenting a challenge to rheumatologists to ensure their patients with systemic lupus erythematosus (SLE) continue to take this essential drug. HCQ is the only SLE treatment shown to increase survival and any change in the HCQ regimen is potentially dangerous. Changes in the HCQ regimen should be made jointly with the patient after a discussion of the available evidence and expert opinion and the patient's preferences. Providers need to make thoughtful, informed decisions in this time of medication shortage.</AbstractText><CopyrightInformation>Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Littlejohn</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Rheumatologic and Immunologic Disease, Cleveland Clinic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cleve Clin J Med</MedlineTA><NlmUniqueID>8703441</NlmUniqueID><ISSNLinking>0891-1150</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32393597</ArticleId><ArticleId IdType="pii">ccjm.87a.ccc023</ArticleId><ArticleId IdType="doi">10.3949/ccjm.87a.ccc023</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001737 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001737 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32393597
|texte= Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32393597" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |